BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 27743200)

  • 21. Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment.
    Kajiura S; Hosokawa A; Yoshita H; Ueda Y; Ueda A; Mihara H; Ando T; Fujinami H; Nishikawa J; Ogawa K; Minemura M; Sugiyama T
    Am J Clin Oncol; 2016 Feb; 39(1):13-7. PubMed ID: 24322336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II study of docetaxel and cisplatin chemotherapy in 5-fluorouracil/cisplatin pretreated esophageal cancer.
    Shim HJ; Cho SH; Hwang JE; Bae WK; Song SY; Cho SB; Lee WS; Joo YE; Na KJ; Chung IJ
    Am J Clin Oncol; 2010 Dec; 33(6):624-8. PubMed ID: 20142726
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [A successful resected case of advanced esophageal cancer with early gastric cancer responding to neoadjuvant chemotherapy of docetaxel, CDDP and 5-FU].
    Matsutani T; Yoshida H; Sasajima K; Maruyama H; Yokoyama T; Matsushita A; Hirakata A; Takao Y; Umakoshi M; Hayakawa T; Katayama H; Hosone M; Uchida E
    Gan To Kagaku Ryoho; 2012 Apr; 39(4):645-8. PubMed ID: 22504694
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer.
    Ilson DH
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 14):22-5. PubMed ID: 15685830
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients.
    Hu G; Wang Z; Wang Y; Zhang Q; Tang N; Guo J; Liu L; Han X
    Drug Des Devel Ther; 2016; 10():2129-36. PubMed ID: 27445460
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
    Al-Batran SE; Hartmann JT; Probst S; Schmalenberg H; Hollerbach S; Hofheinz R; Rethwisch V; Seipelt G; Homann N; Wilhelm G; Schuch G; Stoehlmacher J; Derigs HG; Hegewisch-Becker S; Grossmann J; Pauligk C; Atmaca A; Bokemeyer C; Knuth A; Jäger E;
    J Clin Oncol; 2008 Mar; 26(9):1435-42. PubMed ID: 18349393
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I study of gemcitabine in combination with cisplatin, 5-fluorouracil and folinic acid in patients with advanced esophageal cancer.
    Oettle H; Arnold D; Kern M; Hoepffner N; Settmacher U; Neuhaus P; Riess H
    Anticancer Drugs; 2002 Sep; 13(8):833-8. PubMed ID: 12394268
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of patients with upper gastrointestinal carcinomas.
    Ajani JA
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-72-S19-76. PubMed ID: 9427271
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma.
    Lee J; Im YH; Cho EY; Hong YS; Lee HR; Kim HS; Kim MJ; Kim K; Kang WK; Park K; Shim YM
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):77-84. PubMed ID: 17762932
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
    Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E
    Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group.
    Ajani JA; Moiseyenko VM; Tjulandin S; Majlis A; Constenla M; Boni C; Rodrigues A; Fodor M; Chao Y; Voznyi E; Awad L; Van Cutsem E;
    J Clin Oncol; 2007 Aug; 25(22):3210-6. PubMed ID: 17664468
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase II study of oxaliplatin in combination with leucovorin and fluorouracil as first-line chemotherapy in patients with metastatic squamous cell carcinoma of esophagus.
    Wang J; Chang J; Yu H; Wu X; Wang H; Li W; Ji D; Peng W
    Cancer Chemother Pharmacol; 2013 Apr; 71(4):905-11. PubMed ID: 23370661
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low-dose all-trans retinoic acid enhances cytotoxicity of cisplatin and 5-fluorouracil on CD44(+) cancer stem cells.
    Najafzadeh N; Mazani M; Abbasi A; Farassati F; Amani M
    Biomed Pharmacother; 2015 Aug; 74():243-51. PubMed ID: 26349992
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer.
    Jung JY; Kwon JH; Kim JH; Song HH; Kim I; Lee KS; Kim HJ; Zang DY; Ahn JS; Lee JA; Park YI
    Oncol Rep; 2009 Feb; 21(2):523-9. PubMed ID: 19148531
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase I trial of 5-fluorouracil with cisplatin and concurrent standard-dose radiotherapy in Japanese patients with stage II/III esophageal cancer.
    Nakajima TE; Ura T; Ito Y; Kato K; Minashi K; Nihei K; Hironaka S; Boku N; Kagami Y; Muro K
    Jpn J Clin Oncol; 2009 Jan; 39(1):37-42. PubMed ID: 19103671
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase I and II trial of epirubicin, cisplatin, 24-hour infusion 5 fluorouracil and sodium folinate in patients with advanced esophagogastric carcinomas.
    Karapetis CS; Cheong KA; Yip D; Strickland AH; Steer C; Marx G; Yip S; Chrystal K; Harper PG
    Asia Pac J Clin Oncol; 2010 Dec; 6(4):298-305. PubMed ID: 21114780
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906).
    Kato K; Muro K; Minashi K; Ohtsu A; Ishikura S; Boku N; Takiuchi H; Komatsu Y; Miyata Y; Fukuda H;
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):684-90. PubMed ID: 20932658
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimisation of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of hydroxyurea, leucovorin, 5-FU and cisplatin (HLFP regimen) for metastatic oesophageal cancer.
    Taïeb J; Artru P; Baujat B; Mabro M; Carola E; Maindrault F; Tournigand C; Krulik M; Louvet C; de Gramont A
    Eur J Cancer; 2002 Mar; 38(5):661-6. PubMed ID: 11916548
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer.
    Ross P; Nicolson M; Cunningham D; Valle J; Seymour M; Harper P; Price T; Anderson H; Iveson T; Hickish T; Lofts F; Norman A
    J Clin Oncol; 2002 Apr; 20(8):1996-2004. PubMed ID: 11956258
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium.
    Shah MA; Janjigian YY; Stoller R; Shibata S; Kemeny M; Krishnamurthi S; Su YB; Ocean A; Capanu M; Mehrotra B; Ritch P; Henderson C; Kelsen DP
    J Clin Oncol; 2015 Nov; 33(33):3874-9. PubMed ID: 26438119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.